Every 10-Q that Haemonetics Corporation (HAE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow HAE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HAE filings page.
Haemonetics Corporation reported first-quarter fiscal 2027 net revenues of 339,380 (Dollars in Thousands), up 5.6% compared with the same period a year earlier. Operating income rose 6.7% to 57,458, while net income declined 3.0% to 33,010 and diluted EPS increased 2.9% to $0.72.
Apheresis net revenues grew 5.3%, led by volume growth and share gains in Plasma, and MedSurg revenues increased 6.0% on strength in Vascular Closure and Hemostasis Management. Gross margin remained 59.8%, supported by a shift toward higher-margin offerings and the absence of prior-year inventory fair value step-up amortization.
Net cash provided by operating activities improved to 52,323 from 17,395 (Dollars in Thousands). Cash and cash equivalents were 223,384 against total debt of 1,174,158. During fiscal 2026, the company repurchased 3,009,834 shares for $175.0 million under its 2025 program, leaving $325.0 million authorized as of June 27, 2026.
Haemonetics Corporation reported solid quarterly earnings with softer sales. For the three months ended December 27, 2025, net revenues were $338.97 million, down from $348.54 million a year earlier, while net income increased to $44.74 million from $37.49 million, lifting diluted EPS to $0.95 from $0.74.
For the nine-month period, revenue was $987.68 million versus $1.03 billion, but net income rose to $117.46 million and diluted EPS to $2.46, reflecting stronger gross margins and lower cost of goods sold. Operating cash flow jumped to $222.28 million, supporting acquisitions and share repurchases.
The company continued to reshape its portfolio, completing the Attune Medical and OpSens acquisitions and, subsequent to quarter-end, acquiring Vivasure Medical Limited with $60.7 million paid in cash at closing and potential contingent payments. It also sold its Whole Blood product line for $43.3 million plus contingent consideration and maintained significant leverage through $1.22 billion of total debt, including convertible senior notes due 2026 and 2029.
Haemonetics Corporation reported lower quarterly sales but stronger profitability. For the three months ended September 27, 2025, net revenues were $327.3 million versus $345.5 million a year ago, while gross profit rose to $194.7 million from $187.4 million as cost of goods sold declined. Operating income increased to $58.5 million, and net income was $38.7 million (diluted EPS $0.81) compared with $33.8 million ($0.66) last year.
For the six months ended September 27, 2025, net revenues were $648.7 million versus $681.7 million, and net income was $72.7 million, roughly flat year over year. Operating cash flow strengthened to $128.7 million from $21.4 million, supported by lower inventories and working capital changes.
The company recorded an $8.6 million impairment of certain Hospital business intangibles. It continued portfolio moves: completed the Whole Blood divestiture in January 2025 and executed a new ASR in August 2025, repurchasing $75.0 million of stock (1,430,579 shares at $52.43), leaving $425.0 million authorized under the 2025 program as of September 27, 2025. Shares outstanding were 46,809,672 as of October 31, 2025.